DaVita (DVA)
(Delayed Data from NYSE)
$142.16 USD
-0.53 (-0.37%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $142.12 -0.04 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$142.16 USD
-0.53 (-0.37%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $142.12 -0.04 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DVA vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. USPH: Which Stock Is the Better Value Option?
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.
Varian Medical (VAR) Q3 Earnings: Surprise in Store?
by Zacks Equity Research
Solid prospects in the Oncology segment is likely to boost Varian Medical's (VAR) top-line performance in the third quarter of fiscal 2018.
Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?
by Zacks Equity Research
Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.
Outpatient Market Gains on Social Awareness: 3 Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.
Why Is DaVita (DVA) Up 5.6% Since Its Last Earnings Report?
by Zacks Equity Research
DaVita (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Health Insurance Industry Outlook - May 2018
by Zacks Equity Research
Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.
DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.
Is DaVita (DVA) a Great Stock for Value Investors Right Now?
by Zacks Equity Research
Let's put DaVita (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.
DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues
by Zacks Equity Research
Impressive results from Kidney Care business drove DaVita (DVA) in Q4.
DaVita (DVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.
DaVita (DVA) Partners with Epic to Launch EHR for Patients
by Zacks Equity Research
DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.
Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS
by Zacks Equity Research
Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.
CVS-Aetna Deal Leading a Wave of Change in Hospital Sector
by Zacks Equity Research
Increased consolidation is being witnessed in the hospital sector as a defense against invasion by new comers.
Company News For Dec 7, 2017
by Zacks Equity Research
Companies In The News are: PLAY,OXM,HRB,DVA,UNH
DaVita (DVA) Surges: Stock Moves 13.6% Higher
by Zacks Equity Research
DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes
UnitedHealth to Buy DaVita Medical, Expands Optum Business
by Zacks Equity Research
UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model
UnitedHealth Continues Healthcare Shakeup With DaVita Deal
by Benjamin Rains
On Wednesday, only a few days after the CVS (CVS) and Aetna (AET) deal helped shine a light on the quickly changing healthcare industry, UnitedHealth Group (UNH) announced that it will buy a unit of DaVita Inc. (DVA) for nearly $5 billion.
New Strong Sell Stocks for November 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
Should Value Investors Consider DaVita Inc. (DVA) Stock?
by Zacks Equity Research
Let's put DaVita Inc. (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.
DaVita HealthCare (DVA) Down 9.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval
by Zacks Equity Research
The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
by Zacks Equity Research
DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.